Importance of Metalloproteinase Enzyme Group in Selected Skeletal System Diseases
Abstract
:1. Introduction
2. Bone Tissue Overview
2.1. Cells of Bone Tissue
2.2. Bone Extracellular Matrix
2.3. Bone Remodeling
3. The Role of Metalloproteinases in Physiology and Pathology, with Special Emphasis on Bone Tissue
4. The Role of MMPs in Selected Skeletal Diseases
4.1. Degenerative Spine Disease
4.2. Malignant Diseases of Bone and Dental Cancers
4.2.1. Osteosarcoma
4.2.2. Ewing’s Sarcoma
4.2.3. Chondrosarcoma
4.2.4. Dentigerous Tumors
4.3. Osteoporosis and Osteopenia
4.4. Metastatic Bone Disease
5. Further Research Directions—Sterile Bone Necrosis
6. Summary
Author Contributions
Funding
Conflicts of Interest
References
- Tokuhara, C.K.; Santesso, M.R.; Oliveira, G.S.N.D.; Ventura, T.M.D.S.; Doyama, J.T.; Zambuzzi, W.F.; Oliveira, R.C.D. Updating the Role of Matrix Metalloproteinases in Mineralized Tissue and Related Diseases. J. Appl. Oral Sci. 2019, 27, e20180596. [Google Scholar] [CrossRef]
- Guo, J.; Ren, R.; Sun, K.; He, J.; Shao, J. PERK Signaling Pathway in Bone Metabolism: Friend or Foe? Cell Prolif. 2021, 54, e13011. [Google Scholar] [CrossRef] [PubMed]
- Peres, J.A.; Lamano, T. Strategies for Stimulation of New Bone Formation: A Critical Review. Braz. Dent. J. 2011, 22, 443–448. [Google Scholar] [CrossRef] [PubMed]
- Florencio-Silva, R.; Sasso, G.R.d.S.; Sasso-Cerri, E.; Simões, M.J.; Cerri, P.S. Biology of Bone Tissue: Structure, Function, and Factors That Influence Bone Cells. BioMed Res. Int. 2015, 2015, 421746. [Google Scholar] [CrossRef] [PubMed]
- Laronha, H.; Caldeira, J. Structure and Function of Human Matrix Metalloproteinases. Cells 2020, 9, 1076. [Google Scholar] [CrossRef] [PubMed]
- Theocharis, A.D.; Manou, D.; Karamanos, N.K. The Extracellular Matrix as a Multitasking Player in Disease. FEBS J. 2019, 286, 2830–2869. [Google Scholar] [CrossRef]
- Brauer, P.R. MMPs—Role in Cardiovascular Development and Disease. Front. Biosci. 2006, 11, 447. [Google Scholar] [CrossRef] [PubMed]
- Paiva, K.B.S.; Granjeiro, J.M. Bone Tissue Remodeling and Development: Focus on Matrix Metalloproteinase Functions. Arch. Biochem. Biophys. 2014, 561, 74–87. [Google Scholar] [CrossRef]
- Roy, R.; Morad, G.; Jedinak, A.; Moses, M.A. Metalloproteinases and Their Roles in Human Cancer. Anat. Rec. 2020, 303, 1557–1572. [Google Scholar] [CrossRef]
- Raeeszadeh-Sarmazdeh, M.; Do, L.; Hritz, B. Metalloproteinases and Their Inhibitors: Potential for the Development of New Therapeutics. Cells 2020, 9, 1313. [Google Scholar] [CrossRef]
- Cui, N.; Hu, M.; Khalil, R.A. Biochemical and Biological Attributes of Matrix Metalloproteinases. In Progress in Molecular Biology and Translational Science; Academic Press: Cambridge, MA, USA, 2017; Volume 147, pp. 1–73. [Google Scholar]
- Le Maitre, C.L.; Freemont, A.J.; Hoyland, J.A. Localization of Degradative Enzymes and Their Inhibitors in the Degenerate Human Intervertebral Disc. J. Pathol. 2004, 204, 47–54. [Google Scholar] [CrossRef] [PubMed]
- Dai, Y.; Gan, N. Change of Serum Levels of Matrix Metalloproteinase-13 and Its Inhibitor Factor during Bone Metabolism in Chinese Postmenopausal Women. Clin. Med. China 2013, 12, 1013–1016. [Google Scholar] [CrossRef]
- Korpi, J.T.; Hagström, J.; Lehtonen, N.; Parkkinen, J.; Sorsa, T.; Salo, T.; Laitinen, M. Expression of Matrix Metalloproteinases-2, -8, -13, -26, and Tissue Inhibitors of Metalloproteinase-1 in Human Osteosarcoma. Surg. Oncol. 2011, 20, e18–e22. [Google Scholar] [CrossRef] [PubMed]
- Vaezi, M.A.; Eghtedari, A.R.; Safizadeh, B.; Ghasempour, G.; Salimi, V.; Nourbakhsh, M.; Nazem, S.; Tavakoli-Yaraki, M. Up-Regulation of Matrix Metalloproteinase-9 in Primary Bone Tumors and Its Association with Tumor Aggressiveness. Mol. Biol. Rep. 2022, 49, 9409–9427. [Google Scholar] [CrossRef]
- Kolb, A.D.; Shupp, A.B.; Mukhopadhyay, D.; Marini, F.C.; Bussard, K.M. Osteoblasts Are “Educated” by Crosstalk with Metastatic Breast Cancer Cells in the Bone Tumor Microenvironment. Breast Cancer Res. 2019, 21, 31. [Google Scholar] [CrossRef]
- Paiva, K.B.S.; Granjeiro, J.M. Matrix Metalloproteinases in Bone Resorption, Remodeling, and Repair. In Progress in Molecular Biology and Translational Science; Academic Press: Cambridge, MA, USA, 2017; Volume 147, pp. 203–303. [Google Scholar]
- Delgado-Calle, J.; McAndrews, K.; Wu, G.; Orr, A.L.; Ferrari, A.; Tu, X.; Srinivasan, V.; Roodman, G.D.; Ebetino, F.H.; Boeckman, R.K.; et al. The Notch Pathway Regulates the Bone Gain Induced by PTH Anabolic Signaling. FASEB J. 2022, 36, e22196. [Google Scholar] [CrossRef]
- Srivastava, R.K.; Sapra, L.; Mishra, P.K. Osteometabolism: Metabolic Alterations in Bone Pathologies. Cells 2022, 11, 3943. [Google Scholar] [CrossRef]
- Ponzetti, M.; Rucci, N. Osteoblast Differentiation and Signaling: Established Concepts and Emerging Topics. Int. J. Mol. Sci. 2021, 22, 6651. [Google Scholar] [CrossRef]
- Alford, A.I.; Kozloff, K.M.; Hankenson, K.D. Extracellular Matrix Networks in Bone Remodeling. Int. J. Biochem. Cell Biol. 2015, 65, 20–31. [Google Scholar] [CrossRef]
- Nordin, B.E.C.; Börje, E.C.; Morris, H.A.; Anderson, P. The Physiological Basis of Metabolic Bone Disease; CRC Press: Boca Raton, FL, USA, 2014; ISBN 9781138198708. [Google Scholar]
- Garnero, P. The Role of Collagen Organization on the Properties of Bone. Calcif. Tissue Int. 2015, 97, 229–240. [Google Scholar] [CrossRef] [PubMed]
- Tobeiha, M.; Moghadasian, M.H.; Amin, N.; Jafarnejad, S. RANKL/RANK/OPG Pathway: A Mechanism Involved in Exercise-Induced Bone Remodeling. BioMed Res. Int. 2020, 2020, 6910312. [Google Scholar] [CrossRef] [PubMed]
- Arias, C.F.; Herrero, M.A.; Echeverri, L.F.; Oleaga, G.E.; López, J.M. Bone Remodeling: A Tissue-Level Process Emerging from Cell-Level Molecular Algorithms. PLoS ONE 2018, 13, e0204171. [Google Scholar] [CrossRef] [PubMed]
- Samaras, N.; Papadopoulou, M.A.; Samaras, D.; Ongaro, F. Off-Label Use of Hormones as an Antiaging Strategy: A Review. Clin. Interv. Aging 2014, 9, 1175–1186. [Google Scholar] [CrossRef]
- Batoon, L.; Millard, S.M.; Raggatt, L.J.; Pettit, A.R. Osteomacs and Bone Regeneration. Curr. Osteoporos. Rep. 2017, 15, 385–395. [Google Scholar] [CrossRef]
- Loffek, S.; Schilling, O.; Franzke, C.-W. Biological Role of Matrix Metalloproteinases: A Critical Balance. Eur. Respir. J. 2011, 38, 191–208. [Google Scholar] [CrossRef] [PubMed]
- Jonitz-Heincke, A.; Lochner, K.; Schulze, C.; Pohle, D.; Pustlauk, W.; Hansmann, D.; Bader, R. Contribution of Human Osteoblasts and Macrophages to Bone Matrix Degradation and Proinflammatory Cytokine Release after Exposure to Abrasive Endoprosthetic Wear Particles. Mol. Med. Rep. 2016, 14, 1491–1500. [Google Scholar] [CrossRef]
- Oum’hamed, Z.; Garnotel, R.; Josset, Y.; Trenteseaux, C.; Laurent-Maquin, D. Matrix Metalloproteinases MMP-2, -9 and Tissue Inhibitors TIMP-1, -2 Expression and Secretion by Primary Human Osteoblast Cells in Response to Titanium, Zirconia, and Alumina Ceramics. J. Biomed. Mater. Res. 2004, 68A, 114–122. [Google Scholar] [CrossRef]
- Gong, Y.; Yang, J.; Li, X.; Zhou, C.; Chen, Y.; Wang, Z.; Qiu, X.; Liu, Y.; Zhang, H.; Greenbaum, J.; et al. A Systematic Dissection of Human Primary Osteoblasts in Vivo at Single-Cell Resolution. Aging 2021, 13, 20629–20650. [Google Scholar] [CrossRef]
- Quan, J.; Zhou, C.; Johnson, N.W.; Francis, G.; Dahlstrom, J.E.; Gao, J. Molecular Pathways Involved in Crosstalk between Cancer Cells, Osteoblasts and Osteoclasts in the Invasion of Bone by Oral Squamous Cell Carcinoma. Pathology 2012, 44, 221–227. [Google Scholar] [CrossRef]
- Löfvall, H.; Newbould, H.; Karsdal, M.A.; Dziegiel, M.H.; Richter, J.; Henriksen, K.; Thudium, C.S. Osteoclasts Degrade Bone and Cartilage Knee Joint Compartments through Different Resorption Processes. Arthritis Res. Ther. 2018, 20, 67. [Google Scholar] [CrossRef]
- Hatori, K.; Sasano, Y.; Takahashi, I.; Kamakura, S.; Kagayama, M.; Sasaki, K. Osteoblasts and Osteocytes Express MMP2 and -8 and TIMP1, -2, and -3 along with Extracellular Matrix Molecules during Appositional Bone Formation. Anat. Rec. 2004, 277A, 262–271. [Google Scholar] [CrossRef] [PubMed]
- Weiler, C.; Nerlich, A.; Zipperer, J.; Bachmeier, B.; Boos, N. 2002 SSE Award Competition in Basic Science: Expression of Major Matrix Metalloproteinases Is Associated with Intervertebral Disc Degradation and Resorption. Eur. Spine J. 2002, 11, 308–320. [Google Scholar] [CrossRef]
- Palosaari, H.; Pennington, C.J.; Larmas, M.; Edwards, D.R.; Tjäderhane, L.; Salo, T. Expression Profile of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of MMPs in Mature Human Odontoblasts and Pulp Tissue. Eur. J. Oral Sci. 2003, 111, 117–127. [Google Scholar] [CrossRef]
- Guan, X.; Bartlett, J.D. MMP20 Modulates Cadherin Expression in Ameloblasts as Enamel Develops. J. Dent. Res. 2013, 92, 1123–1128. [Google Scholar] [CrossRef] [PubMed]
- Jain, A.; Bahuguna, R. Role of Matrix Metalloproteinases in Dental Caries, Pulp and Periapical Inflammation: An Overview. J. Oral Biol. Craniofacial Res. 2015, 5, 212–218. [Google Scholar] [CrossRef] [PubMed]
- Prado, P.; Rossy, B.; Molina, B. Metalloproteinases (MMPs) of the Extracellular Matrix in Dentistry. J. Oral Maxillofac. Pathol. 2016, 28, 352–360. [Google Scholar]
- Shin, M.; Chavez, M.B.; Ikeda, A.; Foster, B.L.; Bartlett, J.D. MMP20 Overexpression Disrupts Molar Ameloblast Polarity and Migration. J. Dent. Res. 2018, 97, 820–827. [Google Scholar] [CrossRef]
- Boelen, G.-J.; Boute, L.; d’Hoop, J.; EzEldeen, M.; Lambrichts, I.; Opdenakker, G. Matrix Metalloproteinases and Inhibitors in Dentistry. Clin. Oral Investig. 2019, 23, 2823–2835. [Google Scholar] [CrossRef]
- Anshida, V.; Kumari, R.; Murthy, C.; Samuel, A. Extracellular Matrix Degradation by Host Matrix Metalloproteinases in Restorative Dentistry and Endodontics: An Overview. J. Oral Maxillofac. Pathol. 2020, 24, 352. [Google Scholar] [CrossRef]
- Elgezawi, M.; Haridy, R.; Almas, K.; Abdalla, M.A.; Omar, O.; Abuohashish, H.; Elembaby, A.; Christine Wölfle, U.; Siddiqui, Y.; Kaisarly, D. Matrix Metalloproteinases in Dental and Periodontal Tissues and Their Current Inhibitors: Developmental, Degradational and Pathological Aspects. Int. J. Mol. Sci. 2022, 23, 8929. [Google Scholar] [CrossRef]
- Kasper, G.; Dankert, N.; Tuischer, J.; Hoeft, M.; Gaber, T.; Glaeser, J.D.; Zander, D.; Tschirschmann, M.; Thompson, M.; Matziolis, G.; et al. Mesenchymal Stem Cells Regulate Angiogenesis According to Their Mechanical Environment. Stem Cells 2007, 25, 903–910. [Google Scholar] [CrossRef] [PubMed]
- Guszczyn, T.; Rzeczycka, J.; Popko, J. IGF-I and IGF-Binding Proteins in Articular Exudates of Children with Post-Traumatic Knee Damage and Juvenile Idiopathic Arthritis. Pathobiology 2009, 76, 260–266. [Google Scholar] [CrossRef] [PubMed]
- Po, H.; Liang, H.; Xu, J.; Xue, M.; Jackson, C.J. Matrix Metalloproteinases in Bone Development and Pathology: Current Knowledge and Potential Clinical Utility. Met. Med. 2016, 3, 93–102. [Google Scholar] [CrossRef]
- Li, X.; Zou, Y.; Ding, J.; Ren, X.; Li, L.; Peng, L.; Xiong, Y.; Gan, H.; Xiao, W. The Correlation between Serum MMP-3 and Bone Erosion in Rheumatoid Arthritis. J. Chin. Physician 2021, 23, 227–230, 235. [Google Scholar]
- Zheng, X.; Zhang, Y.; Guo, S.; Zhang, W.; Wang, J.; Lin, Y. Dynamic Expression of Matrix Metalloproteinases 2, 9 and 13 in Ovariectomy-induced Osteoporosis Rats. Exp. Ther. Med. 2018, 16, 1807–1813. [Google Scholar] [CrossRef] [PubMed]
- Sandoval, N.G.; Lima, N.S.C.; Bautz, W.G.; Gama-de-Souza, L.N.; Coburn, K.L.A.; Sandoval, N.G.; Lima, N.S.C.; Bautz, W.G.; Gama-de-Souza, L.N.; Coburn, K.L.A. Matrix Metalloproteinase 2: A Possible Role InTooth Development and Eruption. Odovtos Int. J. Dent. Sci. 2019, 21, 41–51. [Google Scholar] [CrossRef]
- Gadhia, K.; McDonald, S.; Arkutu, N.; Malik, K. Amelogenesis Imperfecta: An Introduction. Br. Dent. J. 2012, 212, 377–379. [Google Scholar] [CrossRef]
- Kim, Y.J.; Kang, J.; Seymen, F.; Koruyucu, M.; Gencay, K.; Shin, T.J.; Hyun, H.-K.; Lee, Z.H.; Hu, J.C.-C.; Simmer, J.P.; et al. Analyses of MMP20 Missense Mutations in Two Families with Hypomaturation Amelogenesis Imperfecta. Front. Physiol. 2017, 8, 229. [Google Scholar] [CrossRef]
- Nikolopoulos, G.; Smith, C.E.L.; Poulter, J.A.; Murillo, G.; Silva, S.; Lamb, T.; Berry, I.R.; Brown, C.J.; Day, P.F.; Soldani, F.; et al. Spectrum of Pathogenic Variants and Founder Effects in Amelogenesis Imperfecta Associated with MMP20. Hum. Mutat. 2021, 42, 567–576. [Google Scholar] [CrossRef]
- Aripaka, S.S.; Bech-Azeddine, R.; Jørgensen, L.M.; Mikkelsen, J.D. The Expression of Metalloproteinases in the Lumbar Disc Correlates Strongly with Pfirrmann MRI Grades in Lumbar Spinal Fusion Patients. Brain Spine 2022, 2, 100872. [Google Scholar] [CrossRef]
- Kushchayev, S.V.; Glushko, T.; Jarraya, M.; Schuleri, K.H.; Preul, M.C.; Brooks, M.L.; Teytelboym, O.M. ABCs of the Degenerative Spine. Insights Imaging 2018, 9, 253–274. [Google Scholar] [CrossRef]
- Pizzini, F.B.; Poletti, M.; Beltramello, A.; Muto, M.; Splendiani, A.; Mehrabi, S.; Costanzo, G.; Vitiello, V.; Barile, A.; Colagrande, S.; et al. Degenerative Spine Disease: Italian Position Paper on Acquisition, Interpretation and Reporting of Magnetic Resonance Imaging. Insights Imaging 2021, 12, 14. [Google Scholar] [CrossRef] [PubMed]
- Bachmeier, B.E.; Nerlich, A.; Mittermaier, N.; Weiler, C.; Lumenta, C.; Wuertz, K.; Boos, N. Matrix Metalloproteinase Expression Levels Suggest Distinct Enzyme Roles during Lumbar Disc Herniation and Degeneration. Eur. Spine J. 2009, 18, 1573–1586. [Google Scholar] [CrossRef] [PubMed]
- Lv, F.-J.; Peng, Y.; Lim, F.L.; Sun, Y.; Lv, M.; Zhou, L.; Wang, H.; Zheng, Z.; Cheung, K.M.C.; Leung, V.Y.L. Matrix Metalloproteinase 12 Is an Indicator of Intervertebral Disc Degeneration Co-Expressed with Fibrotic Markers. Osteoarthr. Cartil. 2016, 24, 1826–1836. [Google Scholar] [CrossRef] [PubMed]
- Crean, J.K.G.; Roberts, S.; Jaffray, D.C.; Eisenstein, S.M.; Duance, V.C. Matrix Metalloproteinases in the Human Intervertebral Disc: Role in Disc Degeneration and Scoliosis. Spine 1997, 22, 2877–2884. [Google Scholar] [CrossRef] [PubMed]
- Liu, Y.; Wang, Y.; Teng, Z.; Chen, J.; Li, Y.; Chen, Z.; Li, Z.; Zhang, Z. Matrix Metalloproteinase 9 Expression and Survival of Patients with Osteosarcoma: A Meta-Analysis. Eur. J. Cancer Care 2017, 26, e12364. [Google Scholar] [CrossRef] [PubMed]
- Roberts, S.; Caterson, B.; Menage, J.; Evans, E.H.; Jaffray, D.C.; Eisenstein, S.M. Matrix Metalloproteinases And Aggrecanase. Spine 2000, 25, 3005–3013. [Google Scholar] [CrossRef]
- Rutges, J.; Kummer, J.; Oner, F.; Verbout, A.; Castelein, R.; Roestenburg, H.; Dhert, W.; Creemers, L. Increased MMP-2 Activity during Intervertebral Disc Degeneration Is Correlated to MMP-14 Levels. J. Pathol. 2008, 214, 523–530. [Google Scholar] [CrossRef]
- Deng, B.; Ren, J.Z.; Meng, X.Q.; Pang, C.G.; Duan, G.Q.; Zhang, J.X.; Zou, H.; Yang, H.Z.; Ji, J.J. Expression Profiles of MMP-1 and TIMP-1 in Lumbar Intervertebral Disc Degeneration. Genet. Mol. Res. 2015, 14, 19080–19086. [Google Scholar] [CrossRef]
- Hingert, D.; Nawilaijaroen, P.; Ekström, K.; Baranto, A.; Brisby, H. Human Levels of MMP-1 in Degenerated Disks Can Be Mitigated by Signaling Peptides from Mesenchymal Stem Cells. Cells Tissues Organs 2020, 209, 144–154. [Google Scholar] [CrossRef]
- Hsu, H.-T.; Yue, C.-T.; Teng, M.-S.; Tzeng, I.-S.; Li, T.-C.; Tai, P.-A.; Huang, K.-F.; Chen, C.-Y.; Ko, Y.-L. Immuohistochemical Score of Matrix Metalloproteinase-1 May Indicate the Severity of Symptomatic Cervical and Lumbar Disc Degeneration. Spine J. 2020, 20, 124–137. [Google Scholar] [CrossRef] [PubMed]
- Wang, J.-Y.; Wu, P.-K.; Chen, P.C.-H.; Yen, C.-C.; Hung, G.-Y.; Chen, C.-F.; Hung, S.-C.; Tsai, S.-F.; Liu, C.-L.; Chen, T.-H.; et al. Manipulation Therapy Prior to Diagnosis Induced Primary Osteosarcoma Metastasis—From Clinical to Basic Research. PLoS ONE 2014, 9, e96571. [Google Scholar] [CrossRef] [PubMed]
- Eaton, B.R.; Schwarz, R.; Vatner, R.; Yeh, B.; Claude, L.; Indelicato, D.J.; Laack, N. Osteosarcoma. Pediatr. Blood Cancer 2021, 68, e28352. [Google Scholar] [CrossRef] [PubMed]
- Belayneh, R.; Fourman, M.S.; Bhogal, S.; Weiss, K.R. Update on Osteosarcoma. Curr. Oncol. Rep. 2021, 23, 71. [Google Scholar] [CrossRef] [PubMed]
- Hadjimichael, A.C.; Foukas, A.F.; Savvidou, O.D.; Mavrogenis, A.F.; Psyrri, A.K.; Papagelopoulos, P.J. The Anti-Neoplastic Effect of Doxycycline in Osteosarcoma as a Metalloproteinase (MMP) Inhibitor: A Systematic Review. Clin. Sarcoma Res. 2020, 10, 7. [Google Scholar] [CrossRef] [PubMed]
- Kang, H.-G.; Kim, H.-S.; Kim, K.-J.; Oh, J.H.; Lee, M.-R.; Seol, S.M.; Han, I. RECK Expression in Osteosarcoma: Correlation with Matrix Metalloproteinases Activation and Tumor Invasiveness. J. Orthop. Res. 2007, 25, 696–702. [Google Scholar] [CrossRef]
- Bjørnland, K.; Flatmark, K.; Pettersen, S.; Aaasen, A.O.; Fodstad, Ø.; Mælandsmo, G.M. Matrix Metalloproteinases Participate in Osteosarcoma Invasion. J. Surg. Res. 2005, 127, 151–156. [Google Scholar] [CrossRef]
- Ferrari, C.; Benassi, M.; Ponticelli, F.; Gamberi, G.; Ragazzini, P.; Pazzaglia, L.; Balladelli, A.; Bertoni, F.; Picci, P. Role of MMP-9 and its Tissue Inhibitor TIMP-1 in Human OsteosarcomaFindings in 42 Patients Followed for 1–16 Years. Acta Orthop. Scand. 2004, 75, 487–491. [Google Scholar] [CrossRef]
- Gong, C.; Sun, K.; Xiong, H.H.; Sneh, T.; Zhang, J.; Zhou, X.; Yan, P.; Wang, J.H. Expression of CXCR4 and MMP-2 Is Associated with Poor Prognosis in Patients with Osteosarcoma. Histol. Histopathol. 2020, 35, 863–870. [Google Scholar] [CrossRef]
- Zhang, M.; Zhang, X. Association of MMP-2 Expression and Prognosis in Osteosarcoma Patients. Int. J. Clin. Exp. Pathol. 2015, 8, 14965. [Google Scholar]
- Han, J.; Yong, B.; Luo, C.; Tan, P.; Peng, T.; Shen, J. High Serum Alkaline Phosphatase Cooperating with MMP-9 Predicts Metastasis and Poor Prognosis in Patients with Primary Osteosarcoma in Southern China. World J. Surg. Oncol. 2012, 10, 37. [Google Scholar] [CrossRef] [PubMed]
- Li, H.; Zhang, K.; Liu, L.; Ouyang, Y.; Bu, J.; Guo, H.; Xiao, T. A Systematic Review of Matrix Metalloproteinase 9 as a Biomarker of Survival in Patients with Osteosarcoma. Tumor. Biol. 2014, 35, 5487–5491. [Google Scholar] [CrossRef]
- Yoo, J.; Jung, J.H.; Choi, H.J.; Kang, S.J.; Lee, A.; Seo, E.J.; Shim, S.I.; Kang, C.S. The Expression of Matrix Metalloproteinase-9 and Tumor Angiogenesis in Human Osteosarcoma. J. Pathol. Transl. Med. 2015, 39, 418–423. [Google Scholar]
- Zhou, J.; Liu, T.; Wang, W. Prognostic Significance of Matrix Metalloproteinase 9 Expression in Osteosarcoma. Medicine 2018, 97, e13051. [Google Scholar] [CrossRef] [PubMed]
- Kunz, P.; Sähr, H.; Lehner, B.; Fischer, C.; Seebach, E.; Fellenberg, J. Elevated Ratio of MMP2/MMP9 Activity Is Associated with Poor Response to Chemotherapy in Osteosarcoma. BMC Cancer 2016, 16, 223. [Google Scholar] [CrossRef]
- Kushlinskii, N.E.; Timofeev, Y.S.; Solov’ev, Y.N.; Gerstein, E.S.; Lyubimova, N.V.; Bulycheva, I.V. Components of the RANK/RANKL/OPG System, IL-6, IL-8, IL-16, MMP-2, and Calcitonin in the Sera of Patients with Bone Tumors. Bull. Exp. Biol. Med. 2014, 157, 520–523. [Google Scholar] [CrossRef]
- Kushlinsky, N.E.; Solovyov, Y.N.; Babkina, I.V.; Gershtein, E.S.; Bulicheva, I.V. Matrix Metalloproteinases 2, 7, 9 and Tissue Inhibitor of Matrix Metalloproteinase-1 in the Sera of Patients with Bone Tumors. Bull. Exp. Biol. Med. 2010, 149, 233–235. [Google Scholar] [CrossRef]
- Kicman, A.; Niczyporuk, M.; Kulesza, M.; Motyka, J.; Ławicki, S. Utility of Matrix Metalloproteinases in the Diagnosis, Monitoring and Prognosis of Ovarian Cancer Patients. Cancer Manag. Res. 2022, 14, 3359–3382. [Google Scholar] [CrossRef]
- Ozdemir, K.; Zengin, I.; Guney Eskiler, G.; Kocer, H.B.; Ozkan, A.D.; Demiray, T.; Sahin, E.O. The Predictive Role of MMP-2, MMP-9, TIMP-1 and TIMP-2 Serum Levels in the Complete Response of the Tumor to Chemotherapy in Breast Cancer Patients. J. Investig. Surg. 2022, 35, 1544–1550. [Google Scholar] [CrossRef]
- Liang, S.; Chang, L. Serum Matrix Metalloproteinase-9 Level as a Biomarker for Colorectal Cancer: A Diagnostic Meta-Analysis. Biomark. Med. 2018, 12, 393–402. [Google Scholar] [CrossRef]
- Brookes, M.J.; Roundhill, E.A.; Jeys, L.; Parry, M.; Burchill, S.A.; Rankin, K.S. Membrane-type 1 Matrix Metalloproteinase as Predictor of Survival and Candidate Therapeutic Target in Ewing Sarcoma. Pediatr. Blood Cancer 2022, 69, e29959. [Google Scholar] [CrossRef] [PubMed]
- Benassi, M.S.; Gamberi, G.; Magagnoli, G.; Molendini, L.; Ragazzini, P.; Merli, M.; Chiesa, F.; Balladelli, A.; Manfrini, M.; Bertoni, F.; et al. Metalloproteinase Expression and Prognosis in Soft Tissue Sarcomas. Ann. Oncol. 2001, 12, 75–80. [Google Scholar] [CrossRef] [PubMed]
- Mateo, E.; Motta, F.; Queiroz, R.; Scrideli, C.; Tone, L. Protein Expression of Matrix Metalloproteinase (MMP-1, -2, -3, -9 and -14) in Ewing Family Tumors and Medulloblastomas of Pediatric Patients. J. Pediatr. Genet. 2015, 1, 181–187. [Google Scholar] [CrossRef]
- Puerto-Camacho, P.; Díaz-Martín, J.; Olmedo-Pelayo, J.; Bolado-Carrancio, A.; Salguero-Aranda, C.; Jordán-Pérez, C.; Esteban-Medina, M.; Álamo-Álvarez, I.; Delgado-Bellido, D.; Lobo-Selma, L.; et al. Endoglin and MMP14 Contribute to Ewing Sarcoma Spreading by Modulation of Cell–Matrix Interactions. Int. J. Mol. Sci. 2022, 23, 8657. [Google Scholar] [CrossRef]
- Yabe, H.; Fukuma, M.; Urano, F.; Yoshida, K.; Kato, S.; Toyama, Y.; Hata, J.; Umezawa, A. Lack of Matrix Metalloproteinase (MMP)-1 and -3 Expression in Ewing Sarcoma May Be Due to Loss of Accessibility of the MMP Regulatory Element to the Specific Fusion Protein in Vivo. Biochem. Biophys. Res. Commun. 2002, 293, 61–71. [Google Scholar] [CrossRef] [PubMed]
- Malcherczyk, D.; Heyse, T.J.; El-Zayat, B.F.; Kunzke, V.; Moll, R.; Fuchs-Winkelmann, S.; Paletta, J.R.J. Expression of MMP-9 Decreases Metastatic Potential of Chondrosarcoma: An Immunohistochemical Study. BMC Musculoskelet. Disord. 2018, 19, 9. [Google Scholar] [CrossRef] [PubMed]
- Scully, S.P.; Berend, K.R.; Qi, W.-N.; Harrelson, J.M. Collagenase Specificity in Chondrosarcoma Metastasis. Braz. J. Med. Biol. Res. 1999, 32, 885–889. [Google Scholar] [CrossRef]
- Berend, K.R.; Toth, A.P.; Harrelson, J.M.; Layfield, L.J.; Hey, L.A.; Scully, S.P. Association between Ratio of Matrix Metalloproteinase-1 to Tissue Inhibitor of Metalloproteinase-1 and Local Recurrence, Metastasis, and Survival in Human Chondrosarcoma*. J. Bone Jt. Surg. 1998, 80, 11–17. [Google Scholar] [CrossRef]
- Yao, M.; Wang, X.; Zhao, Y.; Wang, X.; Gao, F. Expression of MMPs Is Dependent on the Activity of Mitogen-Activated Protein Kinase in Chondrosarcoma. Mol. Med. Rep. 2017, 15, 915–921. [Google Scholar] [CrossRef]
- Sakamoto, A.; Oda, Y.; Iwamoto, Y.; Tsuneyoshi, M. Expression of Membrane Type 1 Matrix Metalloproteinase, Matrix Metalloproteinase 2 and Tissue Inhibitor of Metalloproteinase 2 in Human Cartilaginous Tumors with Special Emphasis on Mesenchymal and Dedifferentiated Chondrosarcoma. J. Cancer Res. Clin. Oncol. 1999, 125, 541–548. [Google Scholar] [CrossRef]
- Soderstrom, M.; Aro, H.T.; Ahonen, M.; Johansson, N.; Aho, A.; Ekfors, T.; Bohling, T.; Kahari, V.M.; Vuorio, E. Expression of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Human ChondrosarcomasNote. APMIS 2001, 109, 305–315. [Google Scholar] [CrossRef] [PubMed]
- Sugita, H.; Osaka, S.; Toriyama, M.; Osaka, E.; Yoshida, Y.; Ryu, J.; Sano, M.; Sugitani, M.; Nemoto, N. Correlation between the Histological Grade of Chondrosarcoma and the Expression of MMPs, ADAMTSs and TIMPs. Anticancer Res. 2004, 24, 4079–4084. [Google Scholar]
- Guan, P.-P.; Yu, X.; Guo, J.-J.; Wang, Y.; Wang, T.; Li, J.-Y.; Konstantopoulos, K.; Wang, Z.-Y.; Wang, P. By Activating Matrix Metalloproteinase-7, Shear Stress Promotes Chondrosarcoma Cell Motility, Invasion and Lung Colonization. Oncotarget 2015, 6, 9140–9159. [Google Scholar] [CrossRef] [PubMed]
- Uría, J.A.; Balbín, M.; López, J.M.; Alvarez, J.; Vizoso, F.; Takigawa, M.; López-Otín, C. Collagenase-3 (MMP-13) Expression in Chondrosarcoma Cells and Its Regulation by Basic Fibroblast Growth Factor. Am. J. Pathol. 1998, 153, 91–101. [Google Scholar] [CrossRef] [PubMed]
- Takata, T.; Zhao, M.; Uchida, T.; Wang, T.; Aoki, T.; Bartlett, J.D.; Nikai, H. Immunohistochemical Detection and Distribution of Enamelysin (MMP-20) in Human Odontogenic Tumors. J. Dent. Res. 2000, 79, 1608–1613. [Google Scholar] [CrossRef]
- Ribeiro, B.F.; Ferreira de Araújo, C.R.; dos Santos, B.R.M.; de Almeida Freitas, R. Immunohistochemical Expression of Matrix Metalloproteinases 1, 2, 7, 9, and 26 in the Calcifying Cystic Odontogenic Tumor. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endodontol. 2011, 112, 609–615. [Google Scholar] [CrossRef]
- Farias, L.C.; Gomes, C.C.; Rodrigues, M.C.; de Castro, W.H.; Lacerda, J.C.T.; e Ferreira, E.F.; Gomez, R.S. Epigenetic Regulation of Matrix Metalloproteinase Expression in Ameloblastoma. BMC Clin. Pathol. 2012, 12, 11. [Google Scholar] [CrossRef]
- Anne, R.; Krisnuhoni, E.; Chotimah, C.; Latief, B.S. Matrix Metalloproteinase-9 (MMP-9) Expression in Different Subtypes of Ameloblastoma. J. Maxillofac. Oral Surg. 2014, 13, 281–285. [Google Scholar] [CrossRef]
- Zhou, Y.-M.; Zhong, Q.-B.; Ye, K.-N.; Wang, H.-Y.; Ren, Z.-H. Expression of Matrix Metalloproteinases in Ameloblastomas and Ameloblastic Carcinoma: Systematic Review and Meta-Analysis. Explor. Res. Hypothesis Med. 2019, 4, 19–28. [Google Scholar] [CrossRef]
- Arceo-Mendoza, R.M.; Camacho, P.M. Postmenopausal Osteoporosis. Endocrinol. Metab. Clin. N. Am. 2021, 50, 167–178. [Google Scholar] [CrossRef]
- Anam, A.K.; Insogna, K. Update on Osteoporosis Screening and Management. Med. Clin. N. Am. 2021, 105, 1117–1134. [Google Scholar] [CrossRef] [PubMed]
- Feng, P.; Zhang, H.; Zhang, Z.; Dai, X.; Mao, T.; Fan, Y.; Xie, X.; Wen, H.; Yu, P.; Hu, Y.; et al. The Interaction of MMP-2/B7-H3 in Human Osteoporosis. Clin. Immunol. 2016, 162, 118–124. [Google Scholar] [CrossRef] [PubMed]
- Guo, L.; Luo, X.; Wu, X.; Xie, H.; Zhou, H.; Zhang, H.; Cao, X.; Liao, E. Relationships between Circulating Matrix Metalloproteinase-1, -2 and Metalloproteinase-1 Levels and Bone Biochemical Markers and Bone Mineral Density in Chinese Postmenopausal Women. Zhonghua Yi Xue Za Zhi 2005, 85, 734–737. [Google Scholar] [PubMed]
- Luo, X.H.; Guo, L.J.; Shan, P.F.; Xie, H.; Wu, X.P.; Zhang, H.; Cao, X.Z.; Yuan, L.Q.; Liao, E.Y. Relationship of Circulating MMP-2, MMP-1, and TIMP-1 Levels with Bone Biochemical Markers and Bone Mineral Density in Postmenopausal Chinese Women. Osteoporos. Int. 2006, 17, 521–526. [Google Scholar] [CrossRef]
- Zhang, H.; Luo, X.; Xie, H.; Wu, X.; Shan, P.; Cao, X.; Liao, E. Age-Related Changes Serum Levels of MMP-1 and MMP-2 in Women: Their Relationship with Bone Biochemical Markers and Bone Mineral Density. Zhonghua Nei Ke Za Zhi 2006, 45, 306–309. [Google Scholar]
- Dai, Y.; Shen, L. Relationships between Serum Osteoprotegerin, Matrix Metalloproteinase-2 Levels and Bone Metabolism in Postmenopausal Women. Chin. Med. J. 2007, 120, 2017–2021. [Google Scholar] [CrossRef]
- Bolton, C.E.; Stone, M.D.; Edwards, P.H.; Duckers, J.M.; Evans, W.D.; Shale, D.J. Circulating Matrix Metalloproteinase-9 and Osteoporosis in Patients with Chronic Obstructive Pulmonary Disease. Chron. Respir. Dis. 2009, 6, 81–87. [Google Scholar] [CrossRef]
- Khalil, A.; Salem, H.; Elsayed, D. Matrix Metalloproteinase as a Marker of Low Bone Mineral Density in Chronic Obstructive Pulmonary Disease. Egypt. J. Chest Dis. Tuberc. 2019, 68, 119. [Google Scholar] [CrossRef]
- Zhang, P.F.; Pan, L.; Luo, Z.Y.; Zhao, H.J.; Cai, S.X. Interrelationship of Circulating Matrix Metalloproteinase-9, TNF-α, and OPG/RANK/RANKL Systems in COPD Patients with Osteoporosis. COPD 2013, 10, 650–656. [Google Scholar] [CrossRef]
- Zhu, W.; Yang, M.L.; Yang, G.Y.; Boden, G.; Li, L. Changes in Serum Runt-Related Transcription Factor 2 Levels after a 6-Month Treatment with Recombinant Human Parathyroid Hormone in Patients with Osteoporosis. J. Endocrinol. Investg. 2012, 35, 602–606. [Google Scholar] [CrossRef]
- Mansell, J.P.; Bailey, A.J. Increased Metabolism of Bone Collagen in Post-Menopausal Female Osteoporotic Femoral Heads. Int. J. Biochem. Cell Biol. 2003, 35, 522–529. [Google Scholar] [CrossRef] [PubMed]
- Toti, P.; Sbordone, C.; Martuscelli, R.; Califano, L.; Ramaglia, L.; Sbordone, L. Gene Clustering Analysis in Human Osteoporosis Disease and Modifications of the Jawbone. Arch. Oral Biol. 2013, 58, 912–929. [Google Scholar] [CrossRef] [PubMed]
- Bektan Kanat, B.; Ulugerger Avci, G.; Bayramlar, O.F.; Unal, D.; Sonmez, O.; Bolayirli, I.M.; Doventas, A.; Erdincler, D.S.; Yavuzer, H. Matrix Metalloproteinases/Tissue Inhibitors of Metalloproteinases Ratio: A Biomarker of Bone Resorption in Geriatric Osteoporosis? Ann. Geriatr. Med. Res. 2023, 27, 151–157. [Google Scholar] [CrossRef] [PubMed]
- Xiao, H.; Shan, L.; Zhu, H.; Xue, F. Effects of Bisphosphonates on Bone Metabolism and Serum Matrix Metalloproteinase Level in Patients with Ankylosing Spondylitis Secondary Osteoporosis. African J. Pharm. Pharmacol. 2012, 6, 1594–1597. [Google Scholar] [CrossRef]
- Thisiadou, K.; Liakopoulos, V.; Dimas, G.; Koliakos, G.; Karamouzis, M. Matrix Metalloproteinase-1 and -2 as Markers of Mineral Bone Disease in Chronic Kidney Disease Patients. Hippokratia 2017, 21, 25. [Google Scholar] [PubMed]
- Nevzorova, V.A.; Kochetkova, E.A.; Ugay, L.G.; Maistrovskaya, Y.V.; Khludeeva, E.A. Role of Vascular Remodeling Markers in the Development of Osteoporosis in Idiopathic Pulmonary Arterial Hypertension. Ter. Arkh. 2016, 88, 65–70. [Google Scholar] [CrossRef]
- Kochetkova, E.; Kochetkova, E.A.; Ugaĭ, L.G.; Maĭstrovskaia, I.V.; Buria, K.A.; Nevzorova, V.A. Role of Matrix Metalloproteinase-9 in the Pathogenesis of Osteoporosis in Patients with Chronic Obstructive Pulmonary Disease. Ter. Arkh. 2012, 84, 37–40. [Google Scholar]
- Filipović, T.; Gopčević, K.; Dimitrijević, S.; Hrković, M.; Backović, A.; Lazović, M. Effects of 12-Week Exercise Program on Enzyme Activity of Serum Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 in Female Patients with Postmenopausal Osteoporosis: A Randomized Control Study. BioMed Res. Int. 2020, 2020, 9758289. [Google Scholar] [CrossRef]
- Maugeri, D.; Mamazza, C.; Giudice, F.L.; Puglisi, N.; Muscoso, E.G.; Rizzotto, M.; Testaì, M.; Bennati, E.; Lentini, A.; Panebianco, P. Interleukin-18 (IL-18) and Matrix Metalloproteinase-9 (MMP-9) in Post-Menopausal Osteoporosis. Arch. Gerontol. Geriatr. 2005, 40, 299–305. [Google Scholar] [CrossRef]
- Lv, X.; Wu, P.; Xiao, S.; Zhang, W.; Li, Y.; Ren, B.; Li, Z.; Xia, K.; Wang, B. Matrix Metalloproteinases in Relation to Bone Mineral Density: A Two-Sample Mendelian Randomization Study. Front. Genet. 2021, 12, 754795. [Google Scholar] [CrossRef]
- Farhan, L.O.; Farhan, A.M.; Obaidi, S.A.; Taha, E.M. A Case-Control Study to Determine Metalloproteinase-12 and Lysyl Oxidase Levels in Iraqi Women with Osteoporosis. Res. J. Pharm. Technol. 2022, 15, 2655–2660. [Google Scholar] [CrossRef]
- Liang, L.; Zhu, D.P.; Guo, S.S.; Zhang, D.; Zhang, T. MMP-1 Gene Polymorphism in Osteoporosis. Eur. Rev. Med. Pharmacol. Sci. 2019, 23, 67–72. [Google Scholar] [CrossRef] [PubMed]
- Kodama, R.; Muraki, S.; Iidaka, T.; Oka, H.; Teraguchi, M.; Kagotani, R.; Asai, Y.; Hashizume, H.; Yoshida, M.; Kawaguchi, H.; et al. Serum Levels of Matrix Metalloproteinase-3 and Autoantibodies Related to Rheumatoid Arthritis in the General Japanese Population and Their Association with Osteoporosis and Osteoarthritis: The ROAD Study. J. Bone Miner. Metab. 2018, 36, 246–253. [Google Scholar] [CrossRef] [PubMed]
- Torres, L.; Klingberg, E.; Nurkkala, M.; Carlsten, H.; Forsblad-d’Elia, H. Hepatocyte Growth Factor Is a Potential Biomarker for Osteoproliferation and Osteoporosis in Ankylosing Spondylitis. Osteoporos. Int. 2019, 30, 441–449. [Google Scholar] [CrossRef] [PubMed]
- Kishimoto, H.; Nishiyama, S.; Yoshinaga, Y.; Aita, T.; Ohashi, K.; Miyawaki, S.; Miyoshi, S.; Yoshihara, Y.; Toda, M.; Tsuno, M. SAT0470 Matrix Metalloproteinase-3 (MMP-3) Correlates with Low Bone Mineral Density (BMD) at the Lumbar Spine, but Not at the Femoral Neck in Patients with Systematic Lupus Erythematosus (SLE). Ann. Rheum. Dis. 2014, 73, 763–764. [Google Scholar] [CrossRef]
- Dai, Y. Correlation of Circulating Matrix Metalloproteinase-3 and Osteopontin Levels with Postmenopausal Osteoporosis. J. Trauma Treat 2013, 2, 171. [Google Scholar] [CrossRef]
- Abdu Allah, A.M.; El Tarhouny, S.A.; Khodeer, S.A.; Shehab-Eldin, W.A. The Value of Osteopontin and Matrix Metalloproteinase-3 in the Assessment of Bone Mineral Density in Postmenopausal Women. Menoufia Med. J. 2017, 30, 1065. [Google Scholar] [CrossRef]
- Viljakainen, H.T.; Koistinen, H.A.; Tervahartiala, T.; Sorsa, T.; Andersson, S.; Mäkitie, O. Metabolic Milieu Associates with Impaired Skeletal Characteristics in Obesity. PLoS ONE 2017, 12, e0179660. [Google Scholar] [CrossRef]
- Ban, J.; Fock, V.; Aryee, D.N.T.; Kovar, H. Mechanisms, Diagnosis and Treatment of Bone Metastases. Cells 2021, 10, 2944. [Google Scholar] [CrossRef]
- Pagnotti, G.M.; Trivedi, T.; Mohammad, K.S. Translational Strategies to Target Metastatic Bone Disease. Cells 2022, 12, 1309. [Google Scholar] [CrossRef]
- Jehn, C.F.; Diel, I.J.; Overkamp, F.; Kurth, A.; Schaefer, R.; Miller, K.; Lüftner, D. Management of Metastatic Bone Disease Algorithms for Diagnostics and Treatment. Anticancer 2016, 36, 2631–2637. [Google Scholar]
- Bonfil, R.D.; Cher, M.L. The role of proteolytic enzymes in metastatic bone disease. IBMS BoneKEy 2011, 8, 16–36. [Google Scholar] [CrossRef]
- Feller, L.; Kramer, B.; Lemmer, J. A short account of metastatic bone disease. Cancer Cell Int. 2011, 11, 24. [Google Scholar] [CrossRef] [PubMed]
- Tauro, M.; Lynch, C.C. Cutting to the Chase: How Matrix Metalloproteinase-2 Activity Controls Breast-Cancer-to-Bone Metastasis. Cancers 2018, 10, 185. [Google Scholar] [CrossRef]
- Incorvaia, L.; Badalamenti, G.; Rini, G.; Arcara, C.; Fricano, S.; Sferrazza, C.; Di Trapani, D.; Gebbia, N.; Leto, G. MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone. Anticancer Res. 2007, 27, 1519–1525. [Google Scholar] [PubMed]
- Li, X.; Jin, L.; Tan, Y. Different roles of matrix metalloproteinase 2 in osteolysis of skeletal dysplasia and bone metastasis (Review). Mol. Med. Rep. 2021, 23, 70. [Google Scholar] [CrossRef] [PubMed]
- Skerenova, M.; Mikulova, V.; Capoun, O.; Zima, T.; Tesarova, P. Circulating tumor cells and serum levels of MMP-2, MMP-9 and VEGF as markers of the metastatic process in patients with high risk of metastatic progression. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc. Czech. Repub. 2017, 161, 272–280. [Google Scholar] [CrossRef]
- Nemeth, J.A.; Yousif, R.; Herzog, M.; Che, M.; Upadhyay, J.; Shekarriz, B.; Bhagat, S.; Mullins, C.; Fridman, R.; Cher, M. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J. Natl. Cancer Inst. 2002, 94, 17–25. [Google Scholar] [CrossRef]
- Pego, E.R.; Fernández, I.; Núñez, M.J. Molecular basis of the effect of MMP-9 on the prostate bone metastasis: A review. Urol. Oncol. 2018, 36, 272–282. [Google Scholar] [CrossRef]
- Pivetta, E.; Scapolan, M.; Pecolo, M.; Wassermann, B.; Abu-Rumeileh, I.; Balestreri, L.; Borsatti, E.; Tripodo, C.; Colombatti, A.; Spessotto, P. MMP-13 stimulates osteoclast differentiation and activation in tumour breast bone metastases. Breast Cancer Res. 2011, 13, R105. [Google Scholar] [CrossRef]
- Pijnenburg, L.; Felten, R.; Javier, R.M. A review of avascular necrosis, of the hip and beyond. Rev. Med. Intern. 2020, 41, 27–36. [Google Scholar] [CrossRef] [PubMed]
- Martin Oliva, X.; Viladot Voegeli, A. Aseptic (avascular) bone necrosis in the foot and ankle. EFORT Open Rev. 2020, 5, 684–690. [Google Scholar] [CrossRef] [PubMed]
- Shah, K.N.; Racine, J.; Jones, L.C.; Aaron, R.K. Pathophysiology and risk factors for osteonecrosis. Curr. Rev. Musculoskelet Med. 2015, 8, 201–209. [Google Scholar] [CrossRef] [PubMed]
INTERVERTEBRAL DISC DEGENERATION |
---|
MMP-2 |
-Higher expression in patients with more advanced IVD [58]. -Positive correlation between expression and the occurrence of clefts and tears in the nucleus pulposus and fractures in the fibrous ring [35]. -Positive correlation between the number of cells immunopositive for MMP-1 and the degree of disc degeneration [12]. |
MMP-9 |
-Higher mRNA and protein expression in IVD patients [58,59,60]. -Higher expression in patients with more advanced IVD [58]. -Positive correlation between expression and the presence of histological changes in the fibrous ring [35]. |
MMP-1 |
-Higher mRNA or protein expression and activity in patients with IVD [12,53] -Higher mRNA or protein expression in patients with more advanced IVD [12,53,62,63] -Positive correlation between expression and the occurrence of clefts and tears in the nucleus pulposus, ruptures in the fibrous ring, and the appearance of histological changes in the vertebra [35]. -Serum levels of MMP-1 higher in patients with more advanced IVD [62]. |
MMP-8 |
-Higher mRNA expression in IVD patients [56]. -Positive correlation between mRNA expression and the presence of histological changes [56]. -Positive correlation between mRNA expression and duration of pain [56]. |
MMP-13 |
-Higher mRNA or protein expression and activity in IVD patients [12,53]. -Positive correlation between the number of cells immunopositive for MMP-13 and the degree of disc degeneration [12]. -Higher mRNA expression in patients with more advanced IVD [53]. |
MMP-3 |
-Higher mRNA or protein expression and activity in IVD patients [12,35,53,60]. -The strongest increase in expression among all MMPs in degenerated discs [56]. -Strongest positive correlation of expression with the presence of histopathologic changes [56]. -Positive correlation between expression and the occurrence of clefts and tears in the nucleus pulposus, and the appearance of histological changes in the vertebra [35]. -Positive correlation between the number of cells immunopositive for MMP-3 and the degree of disc degeneration [12]. |
MMP-10 |
-Higher mRNA or protein expression in patients with IVD [53]. -Higher mRNA or protein expression in patients with more advanced IVD [53]. |
MMP-12 |
-Higher mRNA expression in IVD patients [57]. -Higher mRNA expression in degenerated discs compared to healthy tissues [57]. -Higher expression correlated with expression of fibrosis markers (α-SMA, FSP1, and FAP-α) [57]. |
MMP-14 |
-Higher protein expression in patients with IVD [61]. -Higher protein expression in patients with more advanced IVD [61]. |
BONE CANCERS |
OSTEOSARCOMA |
MMP-2 |
-Confirmed expression in OS samples [14,70,71,72,73] and in OS lung metastases [14]. -Confirmed enzymatic activity in OS samples [69,78]. -High activity [78] and high expression [14] correlated with poor response to treatment. -Simultaneous expression of MMP-2 with CXCR4 [72]. -High expression correlated with the presence of distant metastases, shortened OS and MFS rates [72], and the presence of lung metastases [73]. -Higher MMP-2 concentrations in OS patients compared to healthy subjects [79]. |
MMP-9 |
-Confirmed expression in OS samples [74,75,76,77] and in lung metastases [14]. -Confirmed enzymatic activity in OS samples [69,78]. -High activity correlated with good response to treatment [78]. -Positive correlation of MMP-9 protein expression with serum pre-ALP levels [74]. -High expression found in highly malignant tumors with a tendency toward recurrence and metastasis [15]. -High expression correlated with increased OS mortality [59], shorter OS, presence of metastatic foci [75,77]. -Lower serum concentrations in OS patients compared to healthy patients [80]. |
MMP-8 |
-Confirmed expression in OS samples [14]. -Expression restricted to primary focus only, no expression in metastatic foci [14]. |
MMP-13 |
-Confirmed expression in OS samples [14]. -Expression found in primary and metastatic foci [14]. |
MMP-26 |
-Confirmed expression in OS samples [14]. -Expression found in primary and metastatic foci [14] |
MMP-14 |
-Confirmed expression in OS samples [14]. |
EWING SARCOMA |
MMP-2 |
-Confirmed expression in ES samples [85,86,88]. |
MMP-9 |
-Confirmed expression in ES samples [15,85,86,88]. -Highest expression levels in ES samples [86]. -High mRNA expression correlated with tumor size, high degree of malignancy, chemotherapy status, tendency to recur, and metastasis [15]. -High protein expression correlated with high tumor malignancy, chemotherapy status, and tendency to recur [15]. |
MMP-14 |
-Confirmed expression in ES samples [84,86,87]. -Highest level of expression in ES samples [86]. -Expression found in primary and metastatic foci [87]. -High expression correlated with decreased event-free and overall survival [84]. |
CHONDROSARCOMA |
MMP-2 |
-Confirmed expression in chondrosarcoma samples [93,94,95]. -Expression confirmed in different types of chondrosarcoma—clear-cell chondrosarcomas, mesenchymal chondrosarcomas, conventional chondrosarcomas, and dedifferentiated chondrosarcomas [93]. -High expression correlated with higher histologic grade and a tendency toward recurrence [94,95]. |
MMP-9 |
-Confirmed expression in chondrosarcoma samples [89,94,95]. -High expression correlated with better histological differentiation of the tumor [89]. -High expression correlated with prolonged OS in patients [89]. |
MMP-1 |
-Confirmed expression in chondrosarcoma samples [65,89,90,91,92]. -Expression higher in chondrosarcoma compared to benign lesions [92]. |
MMP-8 |
-Expression low, undetectable in some tumors [90]. |
MMP-13 |
-Confirmed expression present in chondrosarcoma samples [92,95,97]. -Expression higher in chondrosarcoma compared to benign lesions [92]. -Higher MMP-13 expression correlates with higher histological grade [95]. |
MMP-3 |
-Confirmed expression in chondrosarcoma samples [89,95]. |
MMP-7 |
-Confirmed expression in chondrosarcoma samples [95,96]. |
MMP-14 |
-Confirmed expression in chondrosarcoma samples [93]. -Confirmed expression in various types of chondrosarcoma—clear-cell chondrosarcomas, mesenchymal chondrosarcomas, conventional chondrosarcomas, and dedifferentiated chondrosarcomas [93]. |
ODONTOGENIC TUMORS |
Few data on MMP expression and patient prognosis depending on MMP expression. |
MMP-2 |
-Higher among osteoporotic patients than patients with a normal BMD [105,106,107,108,109] and osteopenia patients [106,107,108]. -Confirmed higher protein level in osteoporotic bone tissue in contrast to healthy bone [114]. -Contradictory results regarding the relationship between MMP-2 and bone turnover markers: (a) positive correlation with OC, NTX, BALP [106,107,108], TRACP-5b [117], and sB7-H3 [105], (b) negative correlation with BMD [106,107,108,109], OC [118], BALP, and VDR [117]. |
MMP-9 |
-Confirmed higher among osteoporotic patients than patients with a normal BMD [110,111,112] and osteopenia patients [110,112], -Selected as gene with secondary involvement in osteoporosis [115]. -Among patients with osteoporosis as secondary disease serum MMP-9: (a) negatively correlated with BMD index [110,111,112,119,120], (b) positively correlated with RANKL/OPG ratio [112], β-CTX [120], TNF-α [112], -The level of circulating MMP-9 decreases after osteoporosis management via training or treatment [121,122]. -The level of circulating MMP-9 has shown a high power of the test (AUC = 0.8400) as an osteoporosis blood marker [110]. |
MMP-1 |
-Confirmed higher concentration among patients with osteoporosis than among healthy patients [125]. -Positive correlation with OC, PINP, and β-CTX [118]. |
MMP-8 |
-Among children and adolescents, MMP-8 serum level did not correlate with BMI, nor BALP, CTX, or PINP [131]. |
MMP-13 |
-Confirmed higher MMP-13 serum level: (a) among osteoporotic patients than among patients with a normal BMD [13], (b) among osteopenia patients than among patients with a normal BMD [13]. -Confirmed negative correlation between MMP-13 serum level and BMD index in osteoporotic and osteopenia patients [13]. -In osteoporotic patients’ serum, MMP-13 was: (a) negatively correlated with BALP [113], E2 and OPGL [13], (b) positively correlated with OPG, PINP [13], and Runx2 [113], -In osteopenia patients’ serum, MMP-13 was negatively correlated with E2 and CTX [13] -The level of circulating MMP-13 decreased after osteoporosis management through treatment [13]. |
MMP-3 |
-Conflicting data among patients with osteoporosis as the sole disease: (a) genetically predicted serum level is not associated with BMD [123], (b) in postmenopausal women, a higher serum MMP-3 in osteoporotic women than in women with a normal BMD [114,130], (c) in postmenopausal women with osteopenia, the MMP-3 serum level is higher [130] or shows no difference [114] than in women with a normal BMD, (d) in postmenopausal women with osteopenia, the MMP-3 serum level is lower [114] or shows no difference [130] than in osteoporotic women. -Serum MMP-3 among only postmenopausal women: (a) with osteoporosis, it was correlated negatively with BMD and OPGL [114] and positively with OPG [114] and OPN [130], (b) with osteopenia, it was correlated negatively with the BMD of the lumbar spine and ward angle [114]. -Among patients with autoinflammatory and autoimmune diseases as their primary disease, the MMP-3 serum level was: (a) significantly higher in osteoporotic RA patients than in RA patients with a normal BMD [47], (b) higher (but not significantly) in osteoporotic RA patients than in RA osteopenia patients [47], (c) negatively correlated with the BMD of only the lumbar spine among patients with SLE [128], (d) positively correlated with TRACP-5b, and negatively with BALP and VDR, among patients with ankylosing spondylitis [117]. -MMP-3 is hypothesized to be an initiating factor with OPN of postmenopausal osteoporosis [130]. -In postmenopausal women, MMP-3 was presented as a good candidate for a blood marker for osteoporosis, with high sensitivity (93%), specificity (84%), and power of the test (AUC = 0.9520) [130]. |
MMP-10 |
-Genetically predicted serum level is not associated with BMD [123]. |
MMP-7 |
-Genetically predicted serum level is not associated with BMD [123]. |
MMP-12 |
-Genetically predicted serum level is not associated with BMD [123]. -It has been confirmed that there are no differences in MMP-12 concentration among osteoporosis, osteopenia, and normal-BMD patients [124]. |
STERILE BONE NECROSIS |
-No data are available on the role of MMPs in these diseases. -MMPs may be considered in the future as potential candidates for prognostic and predictive markers. |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kulesza, M.; Kicman, A.; Motyka, J.; Guszczyn, T.; Ławicki, S. Importance of Metalloproteinase Enzyme Group in Selected Skeletal System Diseases. Int. J. Mol. Sci. 2023, 24, 17139. https://doi.org/10.3390/ijms242417139
Kulesza M, Kicman A, Motyka J, Guszczyn T, Ławicki S. Importance of Metalloproteinase Enzyme Group in Selected Skeletal System Diseases. International Journal of Molecular Sciences. 2023; 24(24):17139. https://doi.org/10.3390/ijms242417139
Chicago/Turabian StyleKulesza, Monika, Aleksandra Kicman, Joanna Motyka, Tomasz Guszczyn, and Sławomir Ławicki. 2023. "Importance of Metalloproteinase Enzyme Group in Selected Skeletal System Diseases" International Journal of Molecular Sciences 24, no. 24: 17139. https://doi.org/10.3390/ijms242417139